Anteris is a development-stage medical device company focused on structural heart disease, specifically aortic stenosis, pioneering a biomimetic transcatheter aortic valve replacement (TAVR) technology called the DurAVR® THV System. The company's core innovation is a single-piece, tissue-based valve that leverages its proprietary ADAPT® anti-calcification platform—a decellularized bovine pericardial technology already used in tens of thousands of patients for other cardiac applications—combined with an optimized balloon-expandable delivery system designed to improve durability and hemodynamic performance compared to conventional multi-piece alternatives. Anteris generates minimal revenue at present, remaining pre-commercial while advancing regulatory approval and manufacturing capabilities to serve the large and expanding global TAVR market, which addresses aortic stenosis, a common valvular disease affecting millions of patients in North America and Europe.